For many patients, a 30-second weekly injection is actually higher compliance than fighting the "morning coffee battle" every single day
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
The efficacy of Silybum marianum (L.) Gaertn
Watch video Contact Digital event video 26 August 2020 Pharmacy Practice Research priorities during the COVID-19 pandemic Moderators: Charlotte Verner Rossing and Dalia Dawoud
Heading into January 2026, consumer search behavior shows rising interest in non-prescription approaches to metabolic wellness, particularly around GLP-1-related terminology as prescription medications remain highly discussed and regulated
Phospholipid abnormalities in early Alzheimer's disease Arch Neurol 1995